Clinical observation of bone marrow mesenchymal stem cells transplantation in treatment of 22 patients with aplastic anemia
10.3760/cma.j.issn.1009-9921.2012.02.008
- VernacularTitle:骨髓间充质干细胞移植治疗再生障碍性贫血22例临床观察
- Author:
Yu ZHAN
;
Jiayu CHEN
;
Lingzhen CHEN
;
Wei YU
;
Jinming WU
;
Jia QU
;
Kexin FENG
- Publication Type:Journal Article
- Keywords:
Bone marrow mesenchymal stem cells;
Anemia,aplastic
- From:
Journal of Leukemia & Lymphoma
2012;21(2):91-94
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo explore the efficacy and safety of bone marrow mesenchymal stem cells (BMSC)in treatment of aplastic anemia(AA). MethodsTwenty-two patients with aplastic anemia were enrolled with median age of 31 (12-70) years old,including 11 severe aplastic anemia (SAA),and 3 of whom were cyclosporine and anti-thymocyte globulin-resistant. BMSC were isolated from bone marrow of healthy donors and cultured.The third to fifth generation cells were administered intravenously in 1×106/kg to patients once or twice a week.After infusion,complete blood count,bone marrow aspiration,bone marrow biopsy,flow cytometry analysis of lymphocyte subsets of CD3+ CD4+ and CD3+ CD8+ and clinical symptoms were involved in outcome measurement.ResultsAll patients finished 16-time median (5-83 times) infusions of BMSC with 13-month median (2-33 months) treatment course and 23-month median (2-34 months) follow-up.The total response rate was 72.7 ％(16/22), including one patient with essential cure, 9 with remission, 3 with remarkably improvement and 3 with transfusion interval extension.Two of three front-line immunosuppressiveresistant SAA patients achieved remission. Ten of 14 patients recovered from inverted ratio of CD4+/C8+ cells after BMSC treatment. There were no treatment-related side effects observed in the course of treatment.ConclusionBMSC are effective and safe for the treatment of AA in our preliminary study and they deserve further research with larger-scale and long-term clinical trials.
